linagliptin vs metformin

How to Read This linagliptin vs metformin Comparison

linagliptin is classified in the DPP-4 Inhibitor drug class, while metformin sits within the Biguanide class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.

Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, linagliptin has 5,686 submissions while metformin has 95,854. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known moderate interaction flagged in FDA labeling, attributed to one drug may slow down how fast the other is removed from your body through your kidneys. this can cause a dangerous buildup of medicine and lead to a serious condition called lactic acidosis.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.

A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between linagliptin and metformin - always consult your physician or pharmacist first.